- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00879073
Study Bendamustine Concurrent Whole Brain Radiation Brain Metastases From Solid Tumors
Phase I Study of Bendamustine With Concurrent Whole Brain Radiation Therapy in Patients With Brain Metastases From Solid Tumors
The purpose of this study is to:
- Test the maximum tolerated dose (MTD) of Bendamustine with whole brain radiation therapy (WBRT)
- To determine the plasma pharmacokinetics (a blood test to see how much of the drug is getting into the patient's system and how long it lasts in the system) of Bendamustine
- To determine the presence of Bendamustine in cerebrospinal fluid (CSF) (fluid from the brain and spinal cord) of study patients Bendamustine is approved by the Food and Drug Administration (FDA) for chronic lymphocytic leukemia. However, Bendamustine will be used in this study as an investigational agent.
Study Overview
Detailed Description
Bendamustine will be started in the first group at a dose of 60 mg/m²; patients in group 2 will be given Bendamustine at a dose of 80 mg/m²; patients in Group 3 will be given Bendamustine at 100 mg/m². Each cohort will receive Bendamustine once weekly for a total of 4 weeks.
Approximately 3-6 patients enrolled in this study will receive lumbar punctures. Patients will be told before study enrollment whether they will have a lumbar puncture to withdraw CSF.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Florida
-
Tampa, Florida, United States, 33612
- H. Lee Moffitt Cancer Center & Research Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Pathologically (histologically or cytologically) proven diagnosis of solid tumor malignancy within 5 years of registration. Pathological confirmation by pathologists at Moffitt Cancer Center is required.
- Cerebral metastases from known solid tumors diagnosed by contrast-enhanced brain magnetic resonance imaging (MRI) or contrast-enhanced head computed tomography (CT) for patients unable to receive MRIs
- Single metastases that have been resected
- Patient may have had prior radiosurgery or surgical resection for brain metastasis. Patients should have completed prior therapy at least 14 days but no longer than 56 days prior to study entry.
- Karnofsky Performance Status ≥ 70 within 28 days prior to study entry.
- Expected life span of ≥ 3 months
- Able to tolerate 3 week course of whole brain radiation therapy
- Able to receive a lumbar puncture (for post-MTD patients only)
- Adequate bone marrow, liver and renal function as assessed by the following: Hemoglobin > 9.0 g/dl; Absolute neutrophil count (ANC) > 1,500/mm³; Platelet count > 100,000/mm³; Total bilirubin < 1.5 x upper limit of normal (ULN); Alanine transaminase/Aspartic transaminase (ALT/AST) < 2.5 x the ULN (< 5 x ULN for patients with liver involvement); International normalized ratio (INR) < 1.5 or a prothrombin time/partial thromboplastin time (PT/PTT) within normal limits; Creatinine < 1.5 x ULN
- Women of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the start of treatment.
- Ability to understand and sign a study-specific written informed consent prior to study entry.
- Patients receiving systemic therapy are eligible for this study if given >14 days prior to study entry and given no sooner than >14 days post radiation therapy (RT) completion.
- Complete history and general physical examination within 28 days prior to study entry
Exclusion Criteria:
- Known hypersensitivity to bendamustine or mannitol
- Patients with cerebral metastases from unknown primary tumors
- Patients with cerebral metastases from leukemias or lymphomas
- Patients with uncontrolled systemic cancer (i.e. evidence of systemic disease progression < 3 months prior to study entry)
- Systemic chemotherapy ≤14 days prior to study entry or ≤14 days after completing radiotherapy
- Patients who received prior BCNU wafer (Gliadel®) implantation for surgically resected cerebral metastatic lesions
- Patients with a life expectancy of less than 3 months
- Patients who received prior whole brain radiation therapy. As noted above, patients who received prior radiosurgery are allowed
- Patients with significant hydrocephalous
- Active clinically serious infection > Common Terminology Criteria for Adverse Events (CTCAE) Grade 2
- Pregnant or lactating women
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: A - Cohort 1 Treatment
Cohort 1: Bendamustine 60 mg/m² x 4 weeks
|
Approximately 15-24 study patients will be enrolled in this Phase I trial.
Study patients will receive a weekly dose of IV bendamustine with whole brain radiation therapy for 3 weeks and then receive a fourth dose of IV bendamustine one week after completion of whole brain radiation therapy.
The first dose of IV bendamustine will be given when whole brain radiation is initiated.
Other Names:
|
Experimental: B - Cohort 2 Treatment
Cohort 2: Bendamustine 80 mg/m² x 4 weeks
|
Approximately 15-24 study patients will be enrolled in this Phase I trial.
Study patients will receive a weekly dose of IV bendamustine with whole brain radiation therapy for 3 weeks and then receive a fourth dose of IV bendamustine one week after completion of whole brain radiation therapy.
The first dose of IV bendamustine will be given when whole brain radiation is initiated.
Other Names:
|
Experimental: C - Cohort 3 Treatment
Cohort 3: Bendamustine 100 mg/m² x 4 weeks
|
Approximately 15-24 study patients will be enrolled in this Phase I trial.
Study patients will receive a weekly dose of IV bendamustine with whole brain radiation therapy for 3 weeks and then receive a fourth dose of IV bendamustine one week after completion of whole brain radiation therapy.
The first dose of IV bendamustine will be given when whole brain radiation is initiated.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum Tolerated Dose (MTD)
Time Frame: 24 Weeks per Patient
|
To determine the MTD of bendamustine in combination with WBRT
|
24 Weeks per Patient
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Adverse Events (AEs)
Time Frame: 24 Weeks per Patient
|
To determine the toxicity profile of bendamustine in combination with WBRT
|
24 Weeks per Patient
|
Collaborators and Investigators
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Neoplasms
- Neoplasms by Site
- Neoplastic Processes
- Central Nervous System Neoplasms
- Nervous System Neoplasms
- Neoplasm Metastasis
- Brain Neoplasms
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Bendamustine Hydrochloride
Other Study ID Numbers
- MCC-15690
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Brain Metastases
-
Memorial Sloan Kettering Cancer CenterActive, not recruitingRecurrent Brain Metastases | Progressive Brain MetastasesUnited States
-
AC Camargo Cancer CenterCarl Zeiss Meditec AGTerminatedBrain Metastases, Adult | Central Nervous System MetastasesBrazil
-
Rigshospitalet, DenmarkRecruitingCancer | Brain Metastases, AdultDenmark
-
Susanne RogersUniversity of Basel; Technical University of MunichRecruitingBrain Metastases, AdultSwitzerland
-
British Columbia Cancer AgencyVarian Medical SystemsRecruitingBrain Metastases, AdultCanada
-
IRCCS San RaffaeleRecruitingBrain Metastases, AdultItaly
-
AHS Cancer Control AlbertaRecruitingBrain Metastases, AdultCanada
-
University Health Network, TorontoRecruiting
-
Centre Francois BaclesseGroupement Interrégional de Recherche Clinique et d'Innovation; ANOCEF/IGCNORecruitingHemorrhagic Brain MetastasesFrance
-
Duke UniversityVarian Medical SystemsCompleted
Clinical Trials on Bendamustine
-
University of ArizonaCephalonCompletedOvarian CancerUnited States
-
NYU Langone HealthCephalonTerminated
-
M.D. Anderson Cancer CenterWithdrawnLymphoma | Leukemia
-
M.D. Anderson Cancer CenterCephalonTerminatedAcute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Chronic Myeloid Leukemia | Myelodysplastic SyndromeUnited States
-
Aptevo TherapeuticsCompletedChronic Lymphocytic Leukemia (CLL)United States, Austria, Germany, Poland, Spain
-
Novartis PharmaceuticalsCompletedChronic Lymphocytic Leukemia (CLL) | Leukaemia, Lymphocytic, ChronicUnited States, Belgium, Italy, Greece, Russian Federation, Spain, Poland, Czech Republic
-
Prof. Dr. Wolfgang HiddemannHoffmann-La Roche; Mundipharma Research GmbH & Co KGCompleted
-
CephalonCompletedMultiple MyelomaUnited States
-
Georgetown UniversityGlaxoSmithKline; CephalonTerminatedChronic Lymphocytic Leukemia | Small Lymphocytic LymphomaUnited States
-
Memorial Sloan Kettering Cancer CenterCephalonCompletedLymphoma | Hodgkin's DiseaseUnited States